APA (7th ed.) Citation

Chang, H. W., Frey, G., Wang, J., Liu, H., Xing, C., Chen, J., . . . Short, J. M. Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody–drug conjugate. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Chang, Hwai Wen, Gerhard Frey, Jing Wang, Haizhen Liu, Charles Xing, Jian Chen, William J. Boyle, and Jay M. Short. Preclinical Development of Ozuriftamab Vedotin (BA3021), a Novel ROR2-specific Conditionally Active Biologic Antibody–drug Conjugate. Taylor & Francis Group.

MLA (9th ed.) Citation

Chang, Hwai Wen, et al. Preclinical Development of Ozuriftamab Vedotin (BA3021), a Novel ROR2-specific Conditionally Active Biologic Antibody–drug Conjugate. Taylor & Francis Group.